Longevity & Aging
metformin increases lifespan
In plain terms: Is metformin proven to extend healthy human lifespan?
Leans against Longevity & Aging 🔬 Includes disconfirming
Part of: 💊 metformin
RefutedContestedStrong support
consensus score -0.28
No — the definitive trial (TAME) has not reported outcomes and existing human evidence is indirect/confounded, so "fuzzy/inconclusive" is accurate; corroborates the vault's existing contested state.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
4 support 5 contradict 3 tested null 4 mixed · 16 sources, 9 independent groups
What the evidence shows
Rests on the confounded Bannister-2014 observation (diabetics on metformin outliving non-diabetic controls); metformin alone was NULL in the NIA ITP mice; no completed healthy-human RCT (TAME unrun). Unproven for non-diabetic longevity.
The evidence (20)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Han SY, Yadav MK, Wang JH 2026 · Biomedicines | observational | mixed | low | Review frames metformin as 'therapeutic paradox': geroprotective signals vs potential sarcopenia/muscle harm; net longevity unproven |
| Xiao Y, Liu F, Kong Q, Zhu X, Wang H, Li S, Jiang N, Yu C, Yun L 2022 · Aging Cell | animal | supports | moderate | Metformin extends C. elegans healthspan via SAM restriction/H3K4me3 modifiers; non-mammalian model, mechanism-level |
| Cedillo L, Ahsan FM, Li S, Stuhr NL, Zhou Y, Zhang Y, Adedoja A, Murphy LM, Yerevanian A, Emans S, Dao K, Li Z, Peterson ND, Watrous J, Jain M, Das S, Pukkila-Worley R, Curran SP, Soukas AA 2023 · eLife | animal | supports | moderate | Biguanide/metformin pro-longevity in C. elegans requires ether lipid biosynthesis; model-organism mechanism, not human |
| Corley MJ, Pang APS, Shikuma CM, Ndhlovu LC 2024 · Aging Cell | observational | mixed | low | Retrospective trial analysis: metformin reversed monocyte epigenetic age in virally-suppressed older PLWH; cell-type-specific, small |
| Kulkarni AS, Peck BD, Walton RG, Kern PA, Mar JC, Windham ST, Bamman MM, Barzilai N, Peterson CA 2020 · Aging (Albany) | mechanism | tested-null | low | Metformin blunts skeletal-muscle transcriptome adaptation to resistance training in older adults; undercuts healthy-aging benefit |
| Li X, Celotto S, Pizzol D, Gasevic D, Ji MM, Barnini T, Solmi M, Stubbs B, Smith L, López Sánchez GF, Pesolillo G, Yu Z, Tzoulaki I, Theodoratou E, Ioannidis JPA, Veronese N, Demurtas J 2021 · Eur J Clin Invest | meta-analysis | mixed | high | Umbrella review of meta-analyses: 'we identified 427 different meta-analyses'; 'no association classified as convincing or highly suggestive from meta-analyses of observational studies, but some suggestive/weak associations of metformin use with a lower mortality risk of CVD and cancer'. Largely diabetic populations. Review — zero weight. |
| Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE 2016 · Aging Cell | animal | contradicts | high | FT NIA-ITP metformin alone did NOT extend lifespan; only +rapamycin did |
| Nwanaji-Enwerem JC, Chung FF, Van der Laan L, Novoloaca A, Cuenin C, Johansson H, Bonanni B, Hubbard AE, Smith MT, Hartman SJ, Cardenas A, Sears DD, Herceg Z 2021 · Clinical Epigenetics | RCT | tested-null | low | Post-hoc RCT in overweight breast-cancer survivors: metformin showed no significant effect on epigenetic age measures vs placebo |
| Long DE, Peck BD, Martz JL, Tuggle SC, Bush HM, McGwin G, Kern PA, Bamman MM, Peterson CA 2017 · Trials | RCT | tested-null | low | HUMAN: MASTERS RCT protocol; the trial found metformin BLUNTED resistance-training muscle hypertrophy in seniors — a cost cutting against blanket geroprotection. |
| Onken B, Sedore CA, Coleman-Hulbert AL, Hall D, Johnson E, Jones EG, Banse SA, Huynh P, Guo S, Xue J, Chen E, Harinath G, Foulger AC, Chao EA, Hope J, Bhaumik D, Plummer T, Inman D, Morshead M, Guo M, Lithgow GJ, Phillips PC, Driscoll M 2022 · Aging Cell | animal | mixed | moderate | Across Caenorhabditis species metformin lifespan benefit is genetic-background dependent; not universal, sometimes toxic |
| Zajda A, Huttunen KM, Sikora J, Podsiedlik M, Markowicz-Piasecka M 2020 · Mech Ageing Dev | mechanism | mixed | low | Narrative review: metformin's 'impact on clinical ageing features is still hypothetical'; summarises cell/animal data and ongoing RCTs (e.g. TAME). No new data or pooling — review, zero weight. |
| Morin J, Rolland Y, Bischoff-Ferrari HA, Ocampo A, Perez K 2024 · Aging Cell | observational | contradicts | moderate | Retrospective analysis of >500,000 UK Biobank-scale participants aged 40-70: metformin use was NOT associated with extended lifespan/reduced all-cause mortality in the general population — large observational evidence against a non-diabetic longevity benefit. |
| Madsen KS, Chi Y, Metzendorf MI, Richter B, Hemmingsen B 2019 · Cochrane Database Syst Rev | meta-analysis | contradicts | high | Cochrane: no firm evidence metformin reduces all-cause or CV mortality in people at risk of T2D |
| Yang Y, Lu X, Liu N, Ma S, Zhang H, Zhang Z, Yang K, Jiang M, Zheng Z, Qiao Y, Hu Q, Huang Y, Zhang Y, Xiong M, Liu L, Jiang X, Reddy P, Dong X, Xu F, Wang Q, Zhao Q, Lei J, Sun S, Jing Y, Li J, Cai Y, Fan Y, Yan K, Jing Y, Haghani A, Xing M, Zhang X, Zhu G, Song W, Horvath S, Rodriguez Esteban C, Song M, Wang S, Zhao G, Li W, Izpisua Belmonte JC, Qu J, Zhang W, Liu GH 2024 · Cell | animal | supports | high | 40-month study: metformin decelerates multiple aging-clock/tissue markers in male cynomolgus monkeys; strongest primate support, non-human |
| Monami M, Candido R, Pintaudi B, Targher G, Mannucci E, SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes 2021 · Nutr Metab Cardiovasc Dis | meta-analysis | mixed | high | Updated RCT meta-analysis: metformin no significant effect on all-cause mortality or MACE in T2D; benefit not established |
| Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ 2014 · Diabetes Obes Metab | observational | supports | low | CPRD confounded survivor/prescribing bias; not lifespan-extension proof |
| Murillo-Cancho AF, Lozano-Paniagua D, Nievas-Soriano BJ 2025 · Int J Mol Sci | observational | tested-null | low | HUMAN review: classes metformin as a CR-mimetic whose long-term safety and efficacy in healthy populations remain incompletely defined; hard outcomes (frailty, mortality) unproven — matches inconclusive. |
| Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, Perera R, Plüddemann A, Ramachandran A, Roberts NW, Rose PW, Schweizer A, Viberti G, Holman RR 2012 · Diabetologia | meta-analysis | mixed | high | Collaborative RCT meta-analysis: no clear all-cause mortality or cancer reduction from metformin vs comparators; modest/uncertain |
| Malin SK, Heiston EM, Battillo DJ, Ragland TJ, Gow AJ, Shapses SA, Shah AM, Patrie JT, Barrett EJ 2026 · J Clin Endocrinol Metab | RCT | contradicts | moderate | Metformin blunts vascular insulin-sensitivity gains after exercise training in at-risk adults; interferes with exercise adaptation |
| Newman AA, Grimm NC, Wilburn JR, Schoenberg HM, Trikha SRJ, Luckasen GJ, Biela LM, Melby CL, Bell C 2019 · J Clin Endocrinol Metab | RCT | contradicts | moderate | Notes metformin attenuates favorable physiological adaptations to endurance exercise; counters geroprotective framing in healthy people |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.